Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552508 · ClinicalTrials.gov registry record · Phase 4
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT05552508 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 45 participants.
The verdict
NCT05552508, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
Interventions
- COMBINATION_PRODUCT Benralizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2024-07-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552508
The ClinicalTrials.gov registry entry for NCT05552508 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Benralizumab is the first listed.
NCT05552508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05552508 about?
NCT05552508 is a clinical study titled "BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging". This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
What is the current status of trial NCT05552508?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2022-10-11. Estimated completion is 2024-07-19.
What interventions are being tested in trial NCT05552508?
The interventions under investigation include: Benralizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05552508?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.